{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberConstituency=West+Lancashire&max-date=2019-05-20", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMemberConstituency=West+Lancashire&max-date=2019-05-20", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberConstituency=West+Lancashire&max-date=2019-05-20&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&tablingMemberConstituency=West+Lancashire&max-date=2019-05-20", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberConstituency=West+Lancashire&max-date=2019-05-20", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberConstituency=West+Lancashire&max-date=2019-05-20", "items" : [{"_about" : "http://data.parliament.uk/resources/1127499", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1127499/answer", "answerText" : {"_value" : "
Discussions about managed access agreements for technologies undergoing assessment by the National Institute for Health and Care Excellence (NICE) are rightly held between NHS England as an independent body and the manufacturer concerned. Departmental officials play no role in such discussions, but are in regular contact with NICE and NHS England colleagues about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen) for the treatment of spinal muscular atrophy. Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.<\/p>
<\/p>
NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting of 8 May and NICE is now able to recommend the use of Spinraza for NHS patients in England, subject to a managed access agreement agreed between NHS England and Biogen which makes Spinraza available to children with the most severe form of spinal muscular atrophy available with immediate effect. NICE\u2019s Appraisal Committee\u2019s considerations and recommendations will be contained in the final appraisal document which will be published in due course, with final guidance expected in June 2019.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-29", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "256255"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-29T10:38:01.16Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-20", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Nusinersen"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions his Department has held with (a) NICE, (b) NHS England and (c) Biogen on a Managed Access Agreement for SMA treatment Spinraza.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1538", "label" : {"_value" : "Biography information for Rosie Cooper"} } , "tablingMemberConstituency" : {"_value" : "West Lancashire"} , "tablingMemberPrinted" : [{"_value" : "Rosie Cooper"} ], "uin" : "256254"} , {"_about" : "http://data.parliament.uk/resources/1127500", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1127500/answer", "answerText" : {"_value" : "
Discussions about managed access agreements for technologies undergoing assessment by the National Institute for Health and Care Excellence (NICE) are rightly held between NHS England as an independent body and the manufacturer concerned. Departmental officials play no role in such discussions, but are in regular contact with NICE and NHS England colleagues about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen) for the treatment of spinal muscular atrophy. Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.<\/p>
<\/p>
NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting of 8 May and NICE is now able to recommend the use of Spinraza for NHS patients in England, subject to a managed access agreement agreed between NHS England and Biogen which makes Spinraza available to children with the most severe form of spinal muscular atrophy available with immediate effect. NICE\u2019s Appraisal Committee\u2019s considerations and recommendations will be contained in the final appraisal document which will be published in due course, with final guidance expected in June 2019.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-05-29", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "256254"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-29T10:38:01.217Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-20", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "National Institute for Health and Care Excellence"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, when NICE will publish the outcome of the NICE Evaluation Committee meeting held on 6 March 2019.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1538", "label" : {"_value" : "Biography information for Rosie Cooper"} } , "tablingMemberConstituency" : {"_value" : "West Lancashire"} , "tablingMemberPrinted" : [{"_value" : "Rosie Cooper"} ], "uin" : "256255"} , {"_about" : "http://data.parliament.uk/resources/1126507", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1126507/answer", "answerText" : {"_value" : "
NHS Improvement has advised that the Trust responded to the hon. Member\u2019s letter of 14 March 2019 on 17 May 2019.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1585", "label" : {"_value" : "Biography information for Stephen Hammond"} } , "answeringMemberConstituency" : {"_value" : "Wimbledon"} , "answeringMemberPrinted" : {"_value" : "Stephen Hammond"} , "dateOfAnswer" : {"_value" : "2019-05-21", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-05-21T11:09:33.38Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-14", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Members: Correspondence"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether he holds information on when the hon. Member for West Lancashire will receive a response to correspondence sent to Lancashire Care Foundation Trust on 14 March 2018 on mental health care.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1538", "label" : {"_value" : "Biography information for Rosie Cooper"} } , "tablingMemberConstituency" : {"_value" : "West Lancashire"} , "tablingMemberPrinted" : [{"_value" : "Rosie Cooper"} ], "uin" : "254165"} , {"_about" : "http://data.parliament.uk/resources/1123858", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1123858/answer", "answerText" : {"_value" : "
Information on the number of mental health beds is not held at constituency level. The average number of consultant-led, overnight, mental illness beds available in Lancashire Care NHS Foundation Trust is 518 as at Q3 2018/19.<\/p>
Note:<\/p>
Lancashire Care NHS Foundation Trust (RW5) is used as an indication of consultant-led mental illness beds available in West Lancashire<\/p>
Source: KH03 NHS England and NHS Improvement<\/p>